#USA #eMBR Genomics #Axio BioPharma #MKLP1 Pro #Madison, Wisconsin

eMBR Genomics Partners with Axio BioPharma

In a groundbreaking move for the field of cellular biology, eMBR Genomics has teamed up with Axio BioPharma to deliver the MKLP1 Pro™ antibodies to researchers worldwide. This initiative marks the first time these specialized antibodies, associated with the KIF23 gene, will be commercially available to scientists, providing a crucial tool for those investigating Midbody Remnants (MBRs). As researchers explore the potential of MBRs in cancer detection and treatment, this partnership promises to make significant waves in the scientific community.

What are MBRs?

For years, MBRs were overlooked, considered merely cellular debris. However, innovative insights from Dr. Ahna Skop of eMBR Genomics revealed that these structures could play a critical role in cellular communication and cancer detection. MBRs are created during each cell division and are large extracellular vesicles that harbor the MKLP1 protein or KIF23 gene. This discovery changes how scientists view MBRs, recognizing them for their potential to facilitate early cancer diagnoses.

"MBRs can serve as sophisticated vehicles for delivering genetic material and proteins within the body, enhancing our ability to detect and treat various cancers," explained Dr. Skop. "By making MKLP1 Pro antibodies widely available, we open new avenues for research and potential therapeutic applications."

The Characteristics of MKLP1 Pro Antibodies

The proprietary MKLP1 Pro antibodies are designed specifically to identify MBRs and large extracellular vesicles emitted by dividing cells. Currently offered in two formats—MKLP1 Pro-IgM and MKLP1 Pro-IgG—these antibodies are essential for researchers looking to leverage MBRs in their studies. With the obesity of research methodologies, the capabilities of these antibodies hold great promise for revolutionizing cancer research and diagnostics.

Their association with actively dividing cells presents MKLP1 Pro as a promising diagnostic modality for a myriad of cancers, amplifying the chances for early diagnosis and improved patient treatment strategies.

The Significance of the Partnership

The alliance between eMBR Genomics and Axio BioPharma underscores both companies' commitment to enhancing scientific discovery and improving health outcomes. Justin Byers, Founder and CEO of Axio BioPharma, stated, "The MKLP1 Pro antibody represents not just a significant tool for research but a transformative approach in diagnostics for diseases that are commonly lethal if not caught early."

Roman Gelman, CEO of eMBR Genomics, emphasized the importance of this collaboration by stating that decades of research have culminated in the development of these antibodies. His confidence in Axio BioPharma’s manufacturing expertise led to an exclusive partnership that promises to broaden access for researchers worldwide. Gelman remarks, "This collaboration is a pivotal step toward crafting new standards for early cancer detection."

Immediate Availability of MKLP1 Pro Antibodies

Researchers can now order the MKLP1 Pro antibodies in either IgM or IgG formats through Axio BioPharma’s official website. With this launch, scientists globally are now poised to take on critical research questions regarding cancer biology and therapeutics.

To learn more or place an order, visit www.axiobiopharma.com/mklp1-pro.

About the Companies

Axio BioPharma

Located in Madison, Wisconsin, Axio BioPharma is a Contract Development and Manufacturing Organization (CDMO). The company specializes in antibody manufacturing and process development, employing an innovative AI-driven platform that optimizes the design for scalable manufacturing processes, thereby reducing costs and accelerating development timelines.

eMBR Genomics

eMBR Genomics aims to redefine cancer detection through early, non-invasive liquid biopsies. By focusing on the promise of MBRs, the company is actively contributing to the evolution of diagnostic and therapeutic strategies in healthcare.

In conclusion, the partnership between eMBR Genomics and Axio BioPharma not only paves the way for advanced cancer diagnostic tools but also heralds a new chapter in the understanding of cellular functions, potentially revolutionizing treatment paradigms in oncology.